Clinical trials: Syndrome
Non-Neoplastic Hematologic and Lymphocytic Disorder
Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
This phase II clinical trial studies how well treosulfan and fludarabine phosphate with or without low dose radiation before donor stem cell transplantation works in treating patients with nonmalignant (noncancerous) diseases.
- Trial name
- NCT00919503
- Testing
- Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 98 people
- Sponsor
- Fred Hutchinson Cancer Center
Insomnia, Obstructive Sleep Apnea
Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)
The objective of the study is to determine if treatment with Ramelteon will help to improve insomnia in older adults with co-existent insomnia and sleep apnea. The primary study objective is sleep latency (a measure of insomnia).
- Trial name
- NCT01048242
- Testing
- rozerem
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Pennsylvania
Sepsis, Severe Sepsis
Piperacillin PK Analysis in Severe Sepsis Patients
Antibiotic dosing in septic patients poses a challenge for clinicians due to the pharmacokinetic changes seen in this population.
- Trial name
- NCT02569086
- Testing
- Blood draw
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- University of Aarhus
Myasthenia Gravis
Myasthenia Gravis Inebilizumab Trial
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
- Trial name
- MINT (NCT04524273)
- Testing
- inebilizumab
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 238 people
- Sponsor
- Amgen
Advanced Solid Tumors
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.
- Trial name
- NCT00734305
- Testing
- MM-121
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Merrimack Pharmaceuticals
Fragile X Syndrome
A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome
The purpose of this study is to determine the effectiveness and tolerability of aripiprazole in the treatment of children and adolescents with Fragile X Syndrome.
- Trial name
- NCT00420459
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Chronic Pain, Migraine
Evaluation of a Mind-body Based Application for the Treatment of Chronic/Persistent Pain.
We are investigating the effects of a mind-body based mobile application on the experience of chronic pain. Participants meeting our criteria for chronic pain (confirmed via self-report) will complete an online baseline…
- Conditions
- Chronic Pain, Migraine, Chronic Pain Syndrome
- Trial name
- NCT05090683
- Testing
- Mind-body mobile application
- Where
- Canada
- Volunteers
- 198 people
- Sponsor
- University of the Fraser Valley
Metabolic Syndrome, Obesity
Study of Sildenafil Citrate on Insulin Resistance in African American
Obesity has a greater detrimental impact on the health of African American women than on any other racial or gender group. Nearly 80% of African American women are overweight or obese in the United States.
- Trial name
- NCT01334554
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Vanderbilt University Medical Center
Staphylococcus Aureus Bacteremia
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
This study is a Phase I/II, double-blind, placebo-controlled trial investigating the True Human monoclonal antibody 514G3 in subjects hospitalized with Staphylococcus aureus bacteremia.
- Trial name
- NCT02357966
- Testing
- 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- XBiotech, Inc.
KERATOCONJUNCTIVITIS SICCA, XEROSTOMIA
Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
This study was designed to test the efficacy and safety of low laser therapy to treat the xerostomia of patients with primary Sjogren's Syndrome.
- Conditions
- KERATOCONJUNCTIVITIS SICCA, XEROSTOMIA, SICCA SYNDROME, PRIMARY SJOGREN SYNDROME
- Trial name
- NCT02066896
- Testing
- Lasertherapy
- Where
- Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of São Paulo
Major Depressive Disorder, Soft Tissue Discomfort Syndrome
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™…
- Conditions
- Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
- Trial name
- NCT01035073
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pennsylvania
Tourette Syndrome
Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression
The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics in subjects with medically refractory debilitating Tourette Syndrome.
- Trial name
- NCT05371041
- Testing
- Medtronic Percept Neurostimulator
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Florida
High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
This is a multi-center Phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) tri-specific killer cell engager (TriKE®) for the treatment of CD33-expressing high risk myelodysplastic syndromes, refractory/relapsed acute myeloid…
- Conditions
- High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Systemic Mastocytosis, Mast Cell Leukemia
- Trial name
- NCT03214666
- Testing
- GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GT Biopharma, Inc.
Paroxysmal Nocturnal Hemoglobinuria
REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.
The primary objective of the study is to evaluate the long-term safety, tolerability, and effect on intravascular hemolysis of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- NCT04162470
- Testing
- REGN3918
- Where
- 14 sites in Hong Kong, Hungary and 4 more
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary
Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
The central hypothesis for this work is that platelet - leukocyte interactions play a critical role in the pathogenesis of acute ischemic events.
- Conditions
- Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
- Trial name
- NCT01241903
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Susan Smyth
Turner Syndrome, Renal Insufficiency, Chronic
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
- Conditions
- Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
- Trial name
- OPTIMA (NCT00234533)
- Testing
- Somatropin (rDNA origin)
- Where
- 45 sites in Belgium, Czechia and 12 more
- Volunteers
- 251 people
- Sponsor
- Ipsen
Long COVID, Long COVID-19
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long COVID-19, Long COVID19
- Trial name
- NCT05965752
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- 24 sites in United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Obstructive Sleep Apnea
SleepFlexTM Treatment of Obstructive Sleep Apnea
The purpose of this study is to evaluate the safety and effectiveness of the SleepFlex program for treatment of mild to moderate OSA
- Trial name
- NCT04726514
- Testing
- SleepFlex
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Berendo Scientific, LLC
COVID-19-Induced Parosmia
Stellate Ganglion Block for COVID-induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected.
- Trial name
- SGB (NCT06253806)
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Dry Eye
Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects
The purpose of this study is to demonstrate the superior efficacy of Systane® Balance over Preservative-Free 0.9% Saline following 35 days of QID (4 times a day) dosing in treating dry eye subjects with lipid deficiency.
- Trial name
- NCT01967147
- Testing
- Propylene Glycol, 0.6% eye drops, Preservative-free 0.9% Saline solution
- Volunteers
- 279 people
- Sponsor
- Alcon Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.